Literature DB >> 22729215

Health economics and health technology assessment in Central and Eastern Europe: a dose of reality.

L Gulácsi, E Orlewska, M Péntek.   

Abstract

Mesh：

Year:  2012        PMID： 22729215     DOI： 10.1007/s10198-012-0411-x

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN： 1618-7598


× No keyword cloud information.
  6 in total

Review 1.  Review of NICE's recommendations, 1999-2005.

Authors:  James Raftery
Journal:  BMJ       Date:  2006-05-27

2.  History of health technology assessment in Hungary.

Authors:  László Gulácsi; Valentin Brodszky; Márta Péntek; Szilárd Varga; Gábor Vas; Imre Boncz
Journal:  Int J Technol Assess Health Care       Date:  2009-06-08       Impact factor: 2.188

3.  Health technology assessment in Poland and Scotland: comparison of process and decisions.

Authors:  Katarzyna Kolasa; Radek Wasiak
Journal:  Int J Technol Assess Health Care       Date:  2012-01       Impact factor: 2.188

4.  A review of Health Technology Assessment (HTA) recommendations for drug therapies issued between 2007 and 2009 and their impact on policymaking processes in Poland.

Authors:  Katarzyna Kolasa; Sebastian Schubert; Andrea Manca; Tadeusz Hermanowski
Journal:  Health Policy       Date:  2011-10       Impact factor: 2.980

5.  Largely ignored: the impact of the threshold value for a QALY on the importance of a transferability factor.

Authors:  Pepijn Vemer; Maureen P M H Rutten-van Mölken
Journal:  Eur J Health Econ       Date:  2010-05-30

6.  What values do the public want their health care systems to use in evaluating technologies?

Authors:  Martin J Buxton; James D Chambers
Journal:  Eur J Health Econ       Date:  2011-08
  6 in total
  8 in total

1.  Comparative analysis of decision maker preferences for equity/efficiency attributes in reimbursement decisions in three European countries.

Authors:  Petra Baji; Manuel García-Goñi; László Gulácsi; Emmanouil Mentzakis; Francesco Paolucci
Journal:  Eur J Health Econ       Date:  2015-08-22

Review 2.  Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries.

Authors:  László Gulácsi; Fanni Rencz; Márta Péntek; Valentin Brodszky; Ruth Lopert; Noémi V Hevér; Petra Baji
Journal:  Eur J Health Econ       Date:  2014-05-16

Review 3.  Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries.

Authors:  Márta Péntek; Gyula Poór; Piotr Wiland; Martina Olejárová; Marek Brzosko; Catalin Codreanu; Nóra Brodszky; László Gulácsi
Journal:  Eur J Health Econ       Date:  2014-05-16

4.  HTA in Central and Eastern European countries; the 2001: A Space Odyssey and efficiency gain.

Authors:  L Gulácsi; M Péntek
Journal:  Eur J Health Econ       Date:  2014-09

5.  Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics.

Authors:  Michael D Mandel; Mandel D Michael; Anita Bálint; Barbara D Lovász; László Gulácsi; Bálint Strbák; Petra A Golovics; Klaudia Farkas; Zsuzsanna Kürti; Blanka K Szilágyi; Anna Mohás; Tamás Molnár; Péter L Lakatos
Journal:  Eur J Health Econ       Date:  2014-05-16

Review 6.  REVIEWING TRANSFERABILITY IN ECONOMIC EVALUATIONS ORIGINATING FROM EASTERN EUROPE.

Authors:  Olena Mandrik; Saskia Knies; Zoltan Kalo; Johan L Severens
Journal:  Int J Technol Assess Health Care       Date:  2015       Impact factor: 2.188

Review 7.  Health technology assessment in middle-income countries: recommendations for a balanced assessment system.

Authors:  Dávid Dankó
Journal:  J Mark Access Health Policy       Date:  2014-03-11

8.  Mapping capacity to conduct health technology assessment in Central, Eastern and South-Eastern Europe.

Authors:  Antonio Olry de Labry Lima; Leticia García Mochon; Araceli Caro Martínez; Eva Martín Ruiz; Jaime Espin Balbino
Journal:  Croat Med J       Date:  2016-02       Impact factor: 1.351
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.